
Afzeta 40mg Tablet
Marketer
Sun Pharmaceutical Industries Ltd
Salt Composition
Afatinib dimaleate (40mg)
Overview Afzeta 40mg Tablet
Aztreon 40mg tablets are indicated for treating non-small cell lung cancer in adults with specific epidermal growth factor receptor (EGFR) gene mutations. Administer on an empty stomach, consistently at the same time daily for optimal efficacy. Dosage and frequency are determined by your physician based on your condition and may be adjusted. Strict adherence to your doctor's prescribed regimen is crucial; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may not be apparent for weeks or months; discontinue only under medical supervision. Common side effects encompass diarrhea (which can be severe, requiring prompt medical attention and hydration), rash, xerosis, and nausea. Regular blood tests may be recommended. Photosensitivity is possible; utilize sunscreen and protective clothing when exposed to sunlight. Report ocular pain, redness, or dryness to your doctor. Prior to commencing treatment, disclose any respiratory issues, hepatic or renal impairment, or concurrent use of anti-infectives. Potential drug interactions are significant; inform your healthcare provider of all medications you are taking. This medication is contraindicated during pregnancy and lactation; reliable contraception is essential for female patients undergoing treatment.
Primary Ingredients of Afzeta 40mg Tablet
No text provided to rephrase.
Uses of Afzeta 40mg Tablet
Lung cancer (excluding small cell type)
Major Benefits of Afzeta 40mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Afzeta 40mg Tablet should be taken on an empty stomach.
Common Side effects of Afzeta 40mg Tablet:
- Diarrhea
- Rash
- Dry skin
- Nausea
- Vomiting
- Loss of appetite
- Itching
- Stomatitis (Inflammation of the mouth)
- Nail disorder
How to use Afzeta 40mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the 40mg Afzeta Tablet whole; avoid chewing, crushing, or fracturing it. Administer on an empty stomach.
How Afzeta 40mg Tablet works:
Oncaspar 40mg tablets are an anti-neoplastic agent. Their mechanism involves targeted inhibition of enzyme receptors—EGFR, HER2, and HER4—crucial for cancer cell proliferation. This blockade consequently suppresses downstream signaling cascades, thereby curbing or retarding tumor growth.
SAFETY ADVICE
AlcoholSAFE
Afzeta 40mg Tablet's concurrent use with alcohol does not produce adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Using Afzeta 40mg tablets during pregnancy poses a confirmed risk to the fetus. While generally contraindicated, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of Afzeta 40mg Tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Afzeta 40mg Tablet's effect on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
The use of Afzeta 40mg Tablets in patients with kidney disease is likely safe. Existing evidence indicates dose modification may not be necessary, but physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Afzeta 40mg tablets in patients with liver disease appears to pose minimal risk. Current evidence indicates dose modification may not be necessary, but physician consultation is recommended.
What if you forget to take Afzeta 40mg Tablet :
Omit any missed Afzeta 40mg Tablet dose and resume your usual regimen. Avoid taking a double dose.
Facts to Know About Afzeta 40mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline-Butenamide Hybrid |
| Developing Habits | No. |
| Type of Treatment | Cancer Treatments |
| Action Class | Kinase inhibitors targeting tyrosine |
